Editorial Videos

Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI’s full potential in pharma.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Raj Indupuri, CEO, eClinical Solutions,pharma’s biggest AI adoption hurdles lie in scaling beyond pilots, ensuring data security, and building user trust within a regulated environment.

Raj Indupuri, CEO, eClinical Solutions, touches on AI's transformation of pharma by streamlining clinical development processes, automating data management, accelerating cycle times, and improving decision-making across trials.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Chris O’Dell, SVP of market solutions at Turquoise Health, explains why the administration’s efforts aren’t likely to impact generics in the near future.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Chris O’Dell, SVP of market solutions at Turquoise Health, details the ways that the President’s new program differs from previous programs.

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses why it's important to a shine a light on this aspect of the healthcare ecosystem.

Chris O’Dell, SVP of market solutions at Turquoise Health, explains the timeline to expect changes to prescription drug prices based on current DTC trend.

In this video discussion with Pharmaceutical Executive, Michael J. Hennessy Jr., chairman and CEO of MJH Life Sciences, and Jason Brown, CEO of BPD Healthcare, discuss how the deal came together and what it means for healthcare executives navigating an increasingly complex marketplace.

Explore CEO insights on decision-making in manufacturing, focusing on risk management, packaging challenges, and strategies for product safety and quality.

Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.

Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.

Jesse Mendelsohn, executive vice president at Model N, explains the pros and cons of continuing to pursue DTC programs once the government-run program launches.

Peptilogics Founder and CEO, Jonathan Steckbeck noted that advances in peptide design and safety have positioned the field to address drug-resistant pathogens more effectively.

Peptilogics Founder, CEO, Jonathan Steckbeck, explained that PLG0206 stands apart from current treatments, while the company’s discovery platform transforms drug development from an iterative search process into a data-driven design model.

Jesse Mendelsohn, executive vice president at Model N, discusses how selling drugs directly to patients differs from traditional government programs.

BioLamina CEO Klaus Langhoff-Roos discusses the challenges of scaling stem cell production from lab plates to bioreactors, emphasizing the balance between cost, risk, and speed in advancing laminin-based technologies that could accelerate next-generation cell and gene therapies.

As timelines change, medical affairs teams must adjust their skillsets.

Hunter Smith,CFO of Rhythm Pharmaceuticals, noted that maintaining balance between investor expectations and long-term biotech priorities depends on partnering.

Efforts to regulate pharma prices will impact other sectors of healthcare, with PBMs likely to feel the impact.

Hunter Smith, CFO of Rhythm Pharmaceuticals, explains that in biotech, success often brings greater capital demands before profitability, requiring CFOs to balance continuous fundraising with careful management.

In discussing the evolving role of biotech CFOs, Hunter Smith,CFO of Rhythm Pharmaceuticals, emphasized that today’s finance leaders must act as the “voice of the investor,” ensuring disciplined capital allocation and long-term value creation.

The current administration’s efforts are just the latest attempt from the government to improve drug prices in the US.

Multiple pharma companies have already announced plans to invest in domestic projects.